Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | NOS3 | P29474 | 4/20 | 0.36 |
| ▸ | NOS1 | P29475 | 4/20 | 0.36 |
| ▸ | NOS2 | P35228 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10601682 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL16583523 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL17417853 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL6853620 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL2734323 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL3047 | 1.00 | INMT (1.00) | INMTUSP2ACHENOS3NOS1 | |
| Iodide SCHEMBL23365018 | 0.98 | INMT (0.95) | INMTUSP2ACHENOS3NOS1 | |
| Ammonia Solution, Strong SCHEMBL6834929 | 0.98 | INMT (0.95) | INMTUSP2ACHENOS3NOS1 | |
| Bromide SCHEMBL8469764 | 0.98 | INMT (0.95) | INMTUSP2ACHENOS3NOS1 | |
| SCHEMBL2544511 | 0.98 | INMT (0.95) | INMTUSP2ACHENOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4332111-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | Nippon Shinyaku Co., Ltd. (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-4242216-A2 | ELECTRONIC DEVICE AND COMPOUND | Novaled GmbH (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-2776447-B2 | METHOD FOR PRODUCING OXO-VINYL-IONOL AND O-PROTECTED DERIVATIVES THEREOF | BASF SE (DE) | 2022-01-05 | — | — | EP | disclosed |
| EP-3319955-B1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3667752-A1 | ELECTRONIC DEVICE AND COMPOUND | Novaled GmbH (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-2724388-B1 | ELECTRONIC DEVICE | NOVALED GMBH (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| EP-2776447-B1 | METHOD FOR PRODUCING OXO-VINYL-IONOL AND O-PROTECTED DERIVATIVES THEREOF | BASF SE (DE) | 2018-05-30 | — | — | EP | disclosed |
| EP-2703392-B1 | 5-MEMBERED RING AROMATIC HETEROCYCLIC DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2013017564-A2 | METHOD FOR THE MANUFACTURE OF COMPOUNDS CONTAINING AN ALPHA-OXY PHOSPHORUS GROUP BY USING P-X COMPONENTS | STRAITMARK HOLDING AG (CH) | 2013-02-07 | — | — | WO | disclosed |
| WO-2012175219-A1 | ELECTRONIC DEVICE AND COMPOUND | NOVALED AG (DE) | 2012-12-27 | — | — | WO | disclosed |
| EP-2064228-B1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8236766-B2 | Uses of synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20110212882-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009016663-A1 | AMPHIPHILIC DEXTRIN CONJUGATES AND THEIR USE IN PHARMACEUTICAL FORMULATIONS AS COMPLEXING AGENTS FOR HYDROPHOBIC DRUGS TO IMPROVE THE AQUEOUS SOLUBILITY AND CONSEQUENTLY THE THERAPEUTIC EFFICACY OF THE COMPLEXED DRUGS | ISTITUTO GIANNINA GASLINI (IT) | 2009-02-05 | — | — | WO | disclosed |
| US-20020028939-A1 | Bicyclic amidines, process for their preparation, and their use as catalyst | WERBITZKY OLEG (CH) | 2002-03-07 | — | — | US | disclosed |
| US-6255488-B1 | BICYCLIC AMIDINES HAVING AMINO, HYDROXYL, AND/OR MERCAPTO GROUPS USEFUL AS CATALYSTS FOR PREPARATION OF POLYURETHANES; WHICH BOND FIRMLY TO THE POLYMER WITH NO TENDENCY TOWARDS MIGRATION | LONZA AG (CH) | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028939-A1 | Bicyclic amidines, process for their preparation, and their use as catalyst | CBR1, CBR3, RER1 | INMT 1116/4885USP2 3077/4885ACHE 2601/4885 |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | INMT 1907/4885USP2 1819/4885ACHE 645/4885 |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | OPRK1, OPRL1, OPRD1 | INMT 2197/4885USP2 2214/4885ACHE 619/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | INMT 2434/4885USP2 2376/4885ACHE 544/4885 |
| US-20110212882-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | INMT 288/4885USP2 3196/4885ACHE 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.